Fujifilm Diosynth Biotechnologies pAVEway™: A Novel Platform for the Advanced Production of Protein Therapeutics

Formed in April 2011 following the acquisition of MSD BioManufacturing Network, Fujifilm Diosynth Biotechnologies is a leading provider of contract process development and manufacturing services for the biopharmaceutical industry. The company has over 800 employees operating from two sites in Billingham, UK (formerly Avecia Biologics) and Research Triangle Park, North Carolina, US (formerly Diosynth Biotechnology).

We help our clients succeed by driving products efficiently and rapidly, offering a broad range of cGMP manufacturing scales, services and experience to accommodate clients’ specific clinical and commercial needs. Our novel pAVEway™ technology for the efficient expression of proteins has been developed to help our customers bring their products to clinical manufacture quickly and cost-effectively.

Fast-track biologics process creation and development

The efficient expression of a therapeutic protein in microbial or mammalian cells is often a bottleneck in the production of biopharmaceuticals. pAVEway helps reduce time to clinic and time to market through fast-track process creation and development.

Class-leading fermentation productivity leads to potential for reduced cost of goods, and the technology has been demonstrated across a wide range of biotherapeutic proteins, using a family of expression systems.

Protein expression platform

The pAVEway platform is based on a set of unique protein expression plasmids, which have been developed by Fujifilm Diosynth Biotechnologies. Using DNA looping to control expression, we have created a range of vectors which provide tightly controlled production of the target proteins, whilst allowing very high expression levels.

These vectors are complemented by a range of host strains. By choosing the appropriate combination of plasmid, host strain and fermentation conditions, very high titres have been demonstrated for soluble, insoluble or secreted proteins.

Proven protein production system

pAVEway has a track record for enabling rapid entry into first clinical manufacture from vector construction, and very high fermentation yields have been achieved for a wide range of proteins with over 30 proteins successfully produced using the system.

Biopharmaceutical process development

In addition to our pAVEway technology, our experience ensures process development is applied appropriately, dependent upon the development needs of customer products at different clinical stages. We offer:

  • Microbial and mammalian capability in the development laboratories with multiple fermenters and reactors
  • 100l scale pre-cGMP pilot plant for process demonstration and supply of pre-clinical material

Mammalian and microbial cGMP manufacturing

Our process development capabilities are supported by a broad range of mammalian and microbial cGMP manufacturing capabilities at our sites in Billingham, UK, and Research Triangle Park, NC, US. Together we have over 15 years of experience working with over 140 complex proteins, and have successfully manufactured four approved products, demonstrating our strong track record in navigating the critical path through validation and regulatory approval. Our facilities have received successful regulatory inspections from all key regulatory agencies.

Biopharmaceutical manufacturing support services

The following additional services are offered to reduce complexity and risk of multiple suppliers:

  • cGMP cell banking facilities for production of master and working cell banks
  • Buffer screening studies to support downstream process development
  • Development of stable product formulations
  • Full range of in-house analytical methods
  • Full range of stability testing capabilities for drug substance and drug product

Quality and regulatory support for protein expression

To ensure our customers’ products meet international regulatory requirements, we provide all the necessary quality and regulatory support through an independent quality unit. 

  • Regulatory support for IND/CTA submission, DMF and CMC as required
  • QC analysis and release of raw materials, environmental and water in-process/final, sample retention
  • Ownership and use of qualified or validated methods
  • Quality agreement followed by routine interactions with customer throughout the programme

Make an enquiry

Follow this company

Follow the company to be always up to date with this company

Press Release

New Mammalian cGMP Cell Banking Facility Commissioned by Fujifilm Diosynth Biotechnologies

Fujifilm Diosynth Biotechnologies has announced that it has commissioned on time its new mammalian cGMP Cell Banking Facility (CBF) at its Billingham, UK site.

White Papers

Making the Most of Your Scale Down Model

While process understanding can come from a variety of sources, scaled down process models of unit operations have particular utility.

Address
Fujifilm Diosynth Biotechnologies

Belasis Avenue

Billingham

TS23 1LH

County Durham

United Kingdom

+44 1642 363511 www.fujifilmdiosynth.com

Fujifilm Diosynth Biotechnologies Images

Products and Services

Video

Press Release

30 April 2013

Fujifilm Diosynth Biotechnologies has announced that it has commissioned on time its new mammalian cGMP Cell Banking Facility (CBF) at its Billingham, UK site.

Read more
14 November 2012

Fujifilm Diosynth Biotechnologies has added another licensed product to its list of commercial biopharmaceutical products, following the announcement that ThromboGenics' has received FDA approval for the launch of JETREA® (ocriplasmin) in the USA for the treatment of Symptomatic Vitreomacular Adhesion (VMA).

Read more
14 November 2012

Fujifilm Diosynth Biotechnologies has announced it has entered into a strategic alliance with Piramal Healthcare UK, whereby the two parties will offer the seamless contract development and manufacture of antibody drug conjugates (ADCs), a growing niche in the development of biopharmaceuticals.

Read more
25 June 2012

Fujifilm Diosynth Biotechnologies has announced it is further increasing its contract process development and manufacturing capabilities through the expansion of its services in mammalian cell line development / process development, and the addition of a new multiproduct cGMP facility at its Billingham, UK site.

Read more
2 April 2012

Fujifilm Diosynth Biotechnologies has completed the first phase of a £3m ($4.5m) investment in new equipment and laboratories at its Billingham, UK site.

Read more
30 October 2011

Fujifilm Diosynth Biotechnologies and ContraFect Corporation have announced that they have signed a contract to support the process development and cGMP manufacture of CF-301

Read more
8 March 2011

Fujifilm Corporation and Merck, known as MSD outside the US and Canada, have announced that they have entered into a definitive agreement by which Fujifilm will acquire the Merck BioManufacturing Network, a leading provider of contract manufacturing and development services for the biopharmaceut

Read more
29 May 2007

ACE Pharmaceuticals today announced that the first patient has entered the Phase III trial also known as the Levamisole trial. This trial was accepted by the EMEA by November 2006. The goal of this trial, which was accepted by the EMEA in November 2006, is to assess the efficacy and sa

Read more
9 January 2007

ARTES announces the grant of the European patent on increasing recombinant protein secretion in yeast by co-expression of Calnexin, a protein responsible in intracellular quality control and sorting. In extensive studies, ARTES could show that overexpression of Calnexin results in sign

Read more
19 June 2006

Kiel - Erkrath, June 19, 2006. PROTEO Biotech AG, a wholly owned subsidiary of PROTEO Inc., USA, has signed a cooperation agreement with ARTES Biotechnology GmbH. The aim of the agreement is the marketing of Elafin, the lead product of PROTEO Biotech AG / PROTEO Inc., in India, Egypt and Argentin

Read more

Regional Offices

Fujifilm Diosynth Biotechnologies

Belasis Avenue

Billingham

TS23 1LH

County Durham

United Kingdom

+44 1642 363511 www.fujifilmdiosynth.com
US and Canada

101 J.Morris Commons Lane

Morrisville, NC 27560

California

United States of America

+1 919 337 4477
Rest of World

Belasis Avenue

Billingham

TS23 1LH

County Durham

United Kingdom

+44 1642 363511

Contact company

I have read and accept the terms and conditions and privacy policy.
We'd like to keep you informed about relevant promotions, products and services, if you would like not to receive these, check this box.
If you would like to hear from carefully selected third party companies, check this box
Follow this company to receive notifications when they update.